Todorova N.Maneva K.Ilarionova M.Dudov A.Todorov D.2024-07-102024-07-102024-07-102024-07-102003-01-011310-281810.1080/13102818.2003.10817074SCOPUS_ID:1242351911https://rlib.uctm.edu/handle/123456789/96The antileukemic activity of the original conjugate of anthracycline antitumor antibiotic epirubicin, covalently bond to the biopolymer chitosan was studied. The ascitic form of lymphocytic leukemia P388 (transplantation dose 1 × 106 tumor cells/mouse), in hybrid mice BDF1 was used as leukemic model. A strong antileukemic activity of the studied conjugate was found, with a clear “dose-effect” correlation. The criterion “increase of life span”(ILS%) reached maximally 553.4% for the conjugate, in comparison with maximally 170.8% for the free epirubicin. The conjugate showed several advantages over the free antitumor antibiotic epirubicin: lower toxicity, stronger antileukemic activity and higher therapeutic index. © 2003 Taylor and Francis Group, LLC.enArticle